Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.36 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14899995 | 0.92 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1ALDH1A1CHRM1HRH3 | |
| SCHEMBL27717811 | 0.84 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL28848374 | 0.84 | HRH3 (0.44) | L3MBTL3L3MBTL1ALDH1A1CHRM1HRH3 | |
| SCHEMBL21056389 | 0.83 | ACACB (0.44) | L3MBTL3L3MBTL1CHRM1ACACBACACA | |
| SCHEMBL1464487 | 0.82 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL4072905 | 0.82 | CYP1A2 (0.61) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL3216528 | 0.82 | POLB (0.55) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL23269622 | 0.81 | CYP1A2 (0.59) | L3MBTL3L3MBTL1ALDH1A1CHRM1HRH3 | |
| SCHEMBL12881320 | 0.81 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL11916103 | 0.80 | SIGMAR1 (0.39) | L3MBTL3L3MBTL1CHRM1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| CN-109575045-A | Thienopyrimidines, preparation method, Pharmaceutical composition and its application | 南京红云生物科技有限公司 | 2019-04-05 | — | — | CN | claimed |
| EP-1979375-B9 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LTD (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-1979375-B1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LTD (GB) | 2011-11-23 | — | — | EP | claimed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| CN-110950807-B | Biaryl compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-03-03 | — | — | CN | disclosed |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| CN-109575045-B | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof | 南京红云生物科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-7989416-B2 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| EP-2189472-A1 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae | Novacta Biosystems Limited (GB) | 2010-05-26 | — | — | EP | disclosed |
| EP-2178552-A1 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | Novacta Biosystems Limited (GB) | 2010-04-28 | — | — | EP | disclosed |
| US-20100048459-A1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009010763-A1 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048459-A1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | MLYCD, COASY, AAAS | L3MBTL3 1536/4885L3MBTL1 576/4885ALDH1A1 1139/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | L3MBTL3 2077/4885L3MBTL1 1721/4885ALDH1A1 2596/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | L3MBTL3 1968/4885L3MBTL1 1569/4885ALDH1A1 616/4885 |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | MTPN, NISCH, VIP | L3MBTL3 1747/4885L3MBTL1 995/4885ALDH1A1 3716/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | L3MBTL3 1968/4885L3MBTL1 1569/4885ALDH1A1 616/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | L3MBTL3 1968/4885L3MBTL1 1569/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.